Risperidone instructions for administration

Instructions for administration
Schizophrenia Bipolar mania Irritability associated with autistic disorder (children/adolescents) Dosage in special populations Co-administration of Risperidone with certain other medications Risperdal® M-TAB® orally disintegrating tablets
 * Usual initial dose
 * Maintenance therapy (schizophrenia)
 * Re-initiation of treatment
 * Switching from other antipsychotics
 * Pediatric use (schizophrenia)
 * Usual dose
 * Maintenance therapy (bm)
 * Pediatric use (bm)
 * Tablet accessing
 * Tablet administration

Usual initial dose
Risperidone can be administered on either a BID or a QD schedule. In early clinical trials, Risperidone was generally administered at 1 mg BID initially, with increases in increments of 1 mg BID on the second and third day, as tolerated, to a target dose of 3 mg BID by the third day. Subsequent controlled trials have indicated that total daily risperidone doses of up to 8 mg on a QD regimen are also safe and effective. However, regardless of which regimen is employed, in some patients a slower titration may be medically appropriate. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for the active metabolite would not be achieved for approximately 1 week in the typical patient. When dosage adjustments are necessary, small dose increments/decrements of 1–2 mg are recommended. Efficacy in schizophrenia was demonstrated in a dose range of 4 to 16 mg/day in the clinical trials supporting effectiveness of Risperidone; however, maximal effect was generally seen in a range of 4 to 8 mg/day. Doses above 6 mg/day for BID dosing were not demonstrated to be more efficacious than lower doses, were associated with more extrapyramidal symptoms and other adverse effects, and are not generally recommended. In a single study supporting QD dosing, the efficacy results were generally stronger for 8 mg than for 4 mg. The safety of doses above 16 mg/day has not been evaluated in clinical trials. Return to top

Maintenance therapy (schizophrenia)
While there is no body of evidence available to answer the question of how long the schizophrenic patient treated with Risperidone should remain on it, the effectiveness of Risperidone 2 mg/day to 8 mg/day at delaying relapse was demonstrated in a controlled trial in patients who had been clinically stable for at least 4 weeks and were then followed for a period of 1 to 2 years. In this trial, Risperidone was administered on a QD schedule, at 1 mg QD initially, with increases to 2 mg QD on the second day, and to a target dose of 4 mg QD on the third day. Nevertheless, patients should be periodically reassessed to determine the need for maintenance treatment with an appropriate dose. Return to top

Re-initiation of treatment
Although there are no data to specifically address reinitiation of treatment, it is recommended that when restarting patients who have had an interval off Risperidone, the initial titration schedule should be followed. Return to top

Switching from other antipsychotics
There are no systematically collected data to specifically address switching schizophrenic patients from other antipsychotics to Risperidone, or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some schizophrenic patients, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized. When switching schizophrenic patients from depot antipsychotics, if medically appropriate, initiate Risperidone therapy in place of the next scheduled injection. The need for continuing existing EPS medication should be re-evaluated periodically. Return to top

Pediatric use (schizophrenia)
The safety and effectiveness of Risperidone in pediatric patients with schizophrenia have not been established. Return to top

Usual dose
Risperidone should be administered on a once daily schedule, starting with 2 mg to 3 mg per day. Dosage adjustments, if indicated, should occur at intervals of not less than 24 hours and in dosage increments/decrements of 1 mg per day, as studied in the short-term, placebo-controlled trials. In these trials, short-term (3 week) anti-manic efficacy was demonstrated in a flexible dosage range of 1–6 mg per day. Risperidone doses higher than 6 mg per day were not studied. Return to top

Maintenance therapy (bm)
There is no body of evidence available from controlled trials to guide a clinician in the longer-term management of a patient who improves during treatment of an acute manic episode with risperidone. While it is generally agreed that pharmacological treatment beyond an acute response in mania is desirable, both for maintenance of the initial response and for prevention of new manic episodes, there are no systematically obtained data to support the use of risperidone in such longer-term treatment (i.e., beyond 3 weeks). Return to top

Pediatric use (bm)
The safety and effectiveness of Risperidone in pediatric patients with bipolar mania have not been established. Return to top

Irritability associated with autistic disorder (children/adolescents)
The safety and effectiveness of Risperidone in pediatric patients with autistic disorder less than 5 years of age have not been established. The dosage of Risperidone should be individualized according to the response and tolerability of the patient. The total daily dose of Risperidone can be administered once daily, or half the total daily dose can be administered twice daily. Dosing should be initiated at 0.25 mg per day for patients < 20 kg and 0.5 mg per day for patients ≥ 20 kg. After a minimum of four days from treatment initiation, the dose may be increased to the recommended dose of 0.5 mg per day for patients < 20 kg and 1 mg per day for patients ≥ 20 kg. This dose should be maintained for a minimum of 14 days. In patients not achieving sufficient clinical response, dose increases may be considered at ≥ 2-week intervals in increments of 0.25 mg per day for patients < 20 kg or 0.5 mg per day for patients≥ 20 kg. Caution should be exercised with dosage for smaller children who weigh less than 15 kg. In clinical trials, 90% of patients who showed a response (based on at least 25% improvement on ABC-I) received doses of Risperidone between 0.5 mg and 2.5 mg per day. The maximum daily dose of Risperidone in one of the pivotal trials, when the therapeutic effect reached plateau, was 1.0 mg in patients < 20 kg, 2.5 mg in patients ≥ 20 kg, or 3.0 mg in patients > 45 kg. No dosing data is available for children who weighed less than 15 kg. Once sufficient clinical response has been achieved and maintained, consideration should be given to gradually lowering the dose to achieve the optimal balance of efficacy and safety. Patients experiencing persistent somnolence may benefit from a once daily dose administered at bedtime or administering half the daily dose twice daily, or a reduction of the dose. Return to top

Dosage in special populations
The recommended initial dose is 0.5 mg BID in patients who are elderly or debilitated, patients with severe renal or hepatic impairment, and patients either predisposed to hypotension or for whom hypotension would pose a risk. Dosage increases in these patients should be in increments of no more than 0.5 mg BID. Increases to dosages above 1.5 mg BID should generally occur at intervals of at least 1 week. In some patients, slower titration may be medically appropriate. Elderly or debilitated patients, and patients with renal impairment, may have less ability to eliminate Risperdal® than normal adults. Patients with impaired hepatic function may have increases in the free fraction of risperidone, possibly resulting in an enhanced effect. Patients with a predisposition to hypotensive reactions or for whom such reactions would pose a particular risk likewise need to be titrated cautiously and carefully monitored. If a once-a-day dosing regimen in the elderly or debilitated patient is being considered, it is recommended that the patient be titrated on a twice-a-day regimen for 2–3 days at the target dose. Subsequent switches to a once-a-day dosing regimen can be done thereafter. Return to top

Co-administration of Risperidone with certain other medications
Co-administration of carbamazepine and other enzyme inducers (e.g., phenytoin, rifampin, phenobarbital) with risperidone would be expected to cause decreases in the plasma concentrations of active moiety (the sum of risperidone and 9-hydroxyrisperidone), which could lead to decreased efficacy of risperidone treatment. The dose of risperidone needs to be titrated accordingly for patients receiving these enzyme inducers, especially during initiation or discontinuation of therapy with these inducers. Fluoxetine and paroxetine have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%. The dose of risperidone needs to be titrated accordingly when fluoxetine or paroxetine is co-administered. Return to top

Tablet accessing
Return to top
 * Risperdal® M-TAB® Orally Disintegrating Tablets 0.5 mg, 1 mg, and 2 mg are supplied in blister packs of 4 tablet units each. Do not open the blister until ready to administer. For single tablet removal, separate one of the four blister units by tearing apart at the perforations. Bend the corner where indicated. Peel back foil to expose the tablet. DO NOT push the tablet through the foil because this could damage the tablet.
 * Risperdal® M-TAB® Orally Disintegrating Tablets 3 mg and 4 mg are supplied in a child-resistent pouch containing a blister with 1 tablet each. The child-resistant pouch should be torn open at the notch to access the blister. Do not open the blister until ready to administer. Peel back foil from the side to expose the tablet. DO NOT put the tablet through the foil, because this could damage the tablet.

Tablet administration
Using dry hands, remove the tablet from the blister unit and immediately place the entire Risperdal® M-TAB® Orally Disintegrating Tablet on the tongue. The Risperdal® M-TAB® Orally Disintegrating Tablet should be consumed immediately, as the tablet cannot be stored once removed from the blister unit. Risperdal® M-TAB® Orally Disintegrating Tablets disintegrate in the mouth within seconds and can be swallowed subsequently with or without liquid. Patients should not attempt to split or to chew the tablet. Return to top